Breast Cancer, Panic Disorder, and CYP2D6: A Case Study

被引：0
|
作者：
Rettig, Amy [1 ]
机构：
[1] Ohio State Univ, Arthur G James Canc Hosp, Comprehens Canc Ctr, Columbus, OH 43210 USA
来源：
CLINICAL JOURNAL OF ONCOLOGY NURSING | 2012年 / 16卷 / 03期
关键词：
TAMOXIFEN;
D O I：
10.1188/12.CJON.314-315
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
When patients with breast cancer also present with mental health issues, the psychiatric mental health advanced practice RN is an appropriate provider for treatment and medication management. Collaboration with the oncology advanced practice nurse and the rest of the healthcare team can provide personalized, comprehensive care to this patient population. This article describes one example.
引用
收藏
页码：314 / +
页数：3
相关论文
共 50 条
  • [31] Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment
    T. Ramón y Cajal
    A. Altés
    L. Paré
    E. del Rio
    C. Alonso
    A. Barnadas
    M. Baiget
    Breast Cancer Research and Treatment, 2010, 119 : 33 - 38
  • [32] Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation: a study of mutations CYP2D6*3 and CYP2D6*4
    O. Monek
    G. Paintaud
    Y. Bechtel
    J. P. Miguet
    G. Mantion
    P. R. Bechtel
    European Journal of Clinical Pharmacology, 1998, 54 : 47 - 52
  • [33] Clinical relevance of CYP2D6 genetics for tarnoxifen response in breast cancer
    Brauch, Hiltrud
    Schroth, Werner
    Eichelbaum, Michel
    Schwab, Matthias
    Harbeck, Nadia
    BREAST CARE, 2008, 3 (01) : 43 - 50
  • [34] Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes
    Hwang, G. S.
    Bhat, R.
    Crutchley, R. D.
    Trivedi, M., V
    PHARMACOGENOMICS JOURNAL, 2018, 18 (02): : 201 - 208
  • [35] Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
    Madlensky, L.
    Natarajan, L.
    Tchu, S.
    Pu, M.
    Mortimer, J.
    Flatt, S. W.
    Nikoloff, D. M.
    Hillman, G.
    Fontecha, M. R.
    Lawrence, H. J.
    Parker, B. A.
    Wu, A. H. B.
    Pierce, J. P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (05) : 718 - 725
  • [36] Clinical implications of CYP2D6 genotyping on tamoxifen treatment in breast cancer
    Dezentje, V. O.
    Nortier, J. W. R.
    Guchelaar, H. J.
    van de Velde, C. J. H.
    Gelderblom, H.
    EJC SUPPLEMENTS, 2008, 6 (07): : 56 - 56
  • [37] CYP2D6*4 allele and breast cancer risk: Is there any association?
    Ana Fernández-Santander
    Miguel del Saz Sánchez
    Armando Tejerina Gómez
    Fernando Bandrés Moya
    Clinical and Translational Oncology, 2012, 14 : 157 - 159
  • [38] Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer
    Dezentje, Vincent O.
    Guchelaar, Henk-Jan
    Nortier, Johan W. R.
    van de Velde, Cornelis J. H.
    Gelderblom, Hans
    CLINICAL CANCER RESEARCH, 2009, 15 (01) : 15 - 21
  • [39] Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment
    Ramon y Cajal, T.
    Altes, A.
    Pare, L.
    del Rio, E.
    Alonso, C.
    Barnadas, A.
    Baiget, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (01) : 33 - 38
  • [40] Tamoxifen Resistance and CYP2D6 Copy Numbers in Breast Cancer Patients
    Motamedi, Sahar
    Majidzadeh, Keivan
    Mazaheri, Mahta
    Anbiaie, Robab
    Mortazavizadeh, Seyed Mohammad Reza
    Esmaeili, Rezvan
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (12) : 6101 - 6104
12345